To investigate AML’s impact on the differentiation of endogenous CD8+ T cells and TTCR-C4, patients samples were grouped as AML- (no AML detected, including two prophylactic arm cases)13, or AML+ (blasts evident in BM and/or PB) (Supplementary Table 10, and Supplementary Fig. 18A, B). This evidence concerns the gene CD8A and acute myeloid leukemia.